Loading..
  • Vivesto logo
  • Vivesto logo
Vivesto
  • About Us
  • Technology & Pipeline
  • Governance
  • Investors
  • Media
  • Contact
  • About Us
    • CEO corner
    • Organisation
      • Management
      • Board of Directors
    • Partnering
    • Career
      • Vacant positions
    • Sustainability / Corporate Responsibility
  • Technology & Pipeline
    • XR Technology Platform
      • Benefits
      • Therapeutic focus
      • IP protection
    • Commercialized products
      • Apealea
    • Project Pipeline
      • Cantrixil
      • Docetaxel Micellar
    • Animal Health
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
  • Investors
    • The Share
    • Ownership Structure
    • Financial Reports and Presentations
    • Analyst coverage
    • Prospectuses
    • Archive US listing
      • SEC Filings
      • Info regarding delisting of ADS from NASDAQ US
    • Press releases
    • Financial calendar
    • Subscribe
    • Contact
  • Media
    • Press releases
    • Events
    • Subscribe
    • Image Bank
    • Contact
  • Contact
March 19, 2019

Extraordinary General Meeting 2019

Extraordinary General Meeting was held on March 19, 2019 in Oasmias offices in Uppsala.

The documentation from the Meeting is available in PDF format below.

Documents

  • Minutes
    Swedish 19 March, 2019
  • Notice
    English 5 Febuary, 2019
  • Proxy
    English 2019

Share this page

Calendar

  • August 12, 2025
    Interim report Q2 2025
  • November 11, 2025
    Interim report Q3 2025
  • February 12, 2026
    Interim report Q4 2025
All events
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
Vivesto logo
  • About Us
  • Technology & Pipeline
  • Corporate Governance
  • Investors
  • Media
  • Contact

Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil and Docetaxel micellar, which are being developed for blood cancer and prostate cancer, respectively, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma.

The Share

Follow the share
  • Personal data
  • Cookies

OAS-MA-P-001-SEP2020

Box 3061
169 03 Solna, Sweden
Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com